Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Gastric cancer: Translating novels concepts into clinical practice.

Salati M, Orsi G, Smyth E, Beretta G, De Vita F, Di Bartolomeo M, Fanotto V, Lonardi S, Morano F, Pietrantonio F, Pinto C, Rimassa L, Vasile E, Vivaldi C, Zaniboni A, Ziranu P, Cascinu S.

Cancer Treat Rev. 2019 Sep;79:101889. doi: 10.1016/j.ctrv.2019.101889. Epub 2019 Aug 14. Review.

PMID:
31445415
2.

Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?

Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, Petrelli F.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1095. doi: 10.3390/cancers11081095. Review.

3.

The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.

Salati M, Caputo F, Cunningham D, Marcheselli L, Spallanzani A, Rimini M, Gelsomino F, Reggiani-Bonetti L, Andrikou K, Rovinelli F, Smyth E, Baratelli C, Kouvelakis K, Kalaitzaki R, Gillbanks A, Michalarea V, Cascinu S, Braconi C.

Eur J Cancer. 2019 Aug;117:84-90. doi: 10.1016/j.ejca.2019.05.030. Epub 2019 Jul 2.

4.

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.

Botticelli A, Salati M, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, Giusti R, Mazzotta M, Mazzuca F, Roberto M, Vici P, Pizzuti L, Nuti M, Marchetti P.

J Transl Med. 2019 Mar 27;17(1):99. doi: 10.1186/s12967-019-1847-x.

5.

Noncoding RNA in Cholangiocarcinoma.

Salati M, Braconi C.

Semin Liver Dis. 2019 Feb;39(1):13-25. doi: 10.1055/s-0038-1676097. Epub 2018 Dec 7. Review.

PMID:
30536290
6.

Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications.

Salati M, Valeri N, Spallanzani A, Braconi C, Cascinu S.

Eur J Surg Oncol. 2019 Aug;45(8):1479-1482. doi: 10.1016/j.ejso.2018.11.006. Epub 2018 Nov 10.

PMID:
30448343
7.

Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis.

Salati M, Baldessari C, Calabrese F, Rossi G, Pettorelli E, Grizzi G, Dominici M, Barbieri F.

Case Rep Oncol. 2018 Sep 7;11(3):615-621. doi: 10.1159/000492666. eCollection 2018 Sep-Dec.

8.

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P.

J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3.

9.

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.

Salati M, Baldessari C, Cerbelli B, Botticelli A.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S91-S94. doi: 10.21037/tlcr.2018.01.14. No abstract available.

10.

Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?

Salati M, Di Emidio K, Tarantino V, Cascinu S.

ESMO Open. 2017 Jul 19;2(3):e000206. doi: 10.1136/esmoopen-2017-000206. eCollection 2017. Review.

11.

Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity.

Salati M, Orsi G, Reggiani Bonetti L, Di Benedetto F, Longo G, Cascinu S.

World J Gastrointest Oncol. 2017 Mar 15;9(3):135-141. doi: 10.4251/wjgo.v9.i3.135.

12.

Rectal cancer restaging after neoadjuvant chemoradiation: towards a down-staging score system.

Manenti A, Roncati L, Salati M, Simonini E, Zizzo M, Farinetti A.

J Gastrointest Oncol. 2017 Feb;8(1):187-188. doi: 10.21037/jgo.2016.10.04. No abstract available.

13.

Emerging antibodies for the treatment of pancreatic cancer.

Andrikou K, Peterle C, Pipitone S, Salati M, Cascinu S.

Expert Opin Emerg Drugs. 2017 Mar;22(1):39-51. doi: 10.1080/14728214.2017.1293649. Epub 2017 Feb 28. Review.

PMID:
28253833
14.

Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy.

Salati M, Tarantino V, Maiorana A, Bettelli S, Luminari S.

Hematol Oncol. 2017 Dec;35(4):861-863. doi: 10.1002/hon.2315. Epub 2016 Jun 15.

PMID:
27301994
15.

Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.

Federico M, Luminari S, Pellegrini C, Merli F, Pesce EA, Chauvie S, Gandolfi L, Capodanno I, Salati M, Argnani L, Zinzani PL.

Haematologica. 2016 Apr;101(4):e139-41. doi: 10.3324/haematol.2015.138388. Epub 2015 Dec 24. No abstract available.

16.

Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry.

El Mistiri M, Salati M, Marcheselli L, Attia A, Habil S, Alhomri F, Spika D, Allemani C, Federico M.

Ann Epidemiol. 2015 Aug;25(8):564-8. doi: 10.1016/j.annepidem.2015.03.012. Epub 2015 Mar 21.

PMID:
25911981
17.

Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin.

Salati M, Cesaretti M, Macchia M, Mistiri ME, Federico M.

Mediterr J Hematol Infect Dis. 2014 Jul 1;6(1):e2014048. doi: 10.4084/MJHID.2014.048. eCollection 2014. Review.

18.

Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry.

Biasoli I, Cesaretti M, Bellei M, Maiorana A, Bonacorsi G, Quaresima M, Salati M, Federico M, Luminari S.

Hematol Oncol. 2015 Sep;33(3):147-51. doi: 10.1002/hon.2144. Epub 2014 Apr 29.

PMID:
24777784

Supplemental Content

Loading ...
Support Center